Literature DB >> 24810480

Clinical features and outcomes of influenza infections in lung transplant recipients: a single-season cohort study.

M M Schuurmans1, B D Isenring, C Jungo, J Boeni, N J Mueller, M Kohler, C Benden.   

Abstract

BACKGROUND: For lung transplant recipients (LTRs) influenza infections pose a considerable risk for complications. These infections have mainly been described in hospitalized patients. The aim of this study was to describe characteristics of predominantly outpatient-treated influenza infections.
METHODS: We conducted a single-season (2010/2011) retrospective observational study using database information of our cohort. Patients with evidence for respiratory tract infection received empirical oseltamivir and an oral antibiotic, pending results from nasopharyngeal swab analysis. In laboratory-confirmed influenza infection, treatment was continued and serial weekly swabs were performed until virologic results were negative.
RESULTS: We identified 22 infections in 21 of 173 patients followed up; influenza A virus was diagnosed in 13 and influenza B virus in 9 infections. Leading presenting symptoms were cough and rhinorrhea. Oseltamivir was given within 48 h of symptom onset in 13 infections and within 72 h in 21 infections. Prolonged viral shedding (PVS) for ≥ 7 days was detected in 15 infections; median shedding duration for influenza A was 21 days. In univariable analysis, viral load (VL) at diagnosis was associated with extended duration of shedding (P = 0.006). Multivariable analysis confirmed this association. Bronchiolitis obliterans syndrome stage increased in 3 patients at 6-month follow-up.
CONCLUSION: In this study, PVS of influenza virus was detected in the majority of LTRs and high VL at diagnosis was predictive for prolonged shedding, which occurred despite extended antiviral therapy.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  infection; influenza; lung transplantation; outpatient; prolonged viral shedding; viral load

Mesh:

Substances:

Year:  2014        PMID: 24810480     DOI: 10.1111/tid.12228

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  5 in total

Review 1.  How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

Review 2.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

3.  Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy.

Authors:  L Richardson; J Brite; M Del Castillo; T Childers; A Sheahan; Y-T Huang; E Dougherty; N E Babady; K Sepkowitz; M Kamboj
Journal:  Clin Microbiol Infect       Date:  2015-12-19       Impact factor: 8.067

4.  Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study.

Authors:  Isabel E Akers; Rainer Weber; Hugo Sax; Jürg Böni; Alexandra Trkola; Stefan P Kuster
Journal:  Influenza Other Respir Viruses       Date:  2017-05-12       Impact factor: 4.380

Review 5.  A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses.

Authors:  Emily S Bailey; Juliana N Zemke; Jessica Y Choi; Gregory C Gray
Journal:  Front Immunol       Date:  2019-12-19       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.